Working… Menu

Safety & Efficacy Study of Subcutaneous Tetrodotoxin for Moderate to Severe Inadequately Controlled Cancer-related Pain (TEC-006)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00725114
Recruitment Status : Completed
First Posted : July 30, 2008
Last Update Posted : July 9, 2014
Information provided by (Responsible Party):
Wex Pharmaceuticals Inc.

Brief Summary:

Different pathophysiologic mechanisms are responsible for the development of chronic pain disorders. Pain pathways are triggered in part by ectopic discharges of voltage-sensitive sodium channels, which are in abundance in both the peripheral and the central nervous systems. Tetrodotoxin (TTX) is a selective blocker of Na+ channels and causes analgesia either by decreasing the propagation of action potentials by Na+ channels and/or by blocking of ectopic discharges associated with chronic pain. TTX is extracted from the puffer fish (fugu). Results from animal pharmacology studies revealed that TTX is a more potent analgesic than standard analgesic agents such as aspirin, morphine or meperidine.

At present, the management of severe cancer pain generally includes the use of opiates. This can often result in undesirable side effects, and treatment with this type of medication is not always effective. Because currently available pain-relieving therapy is unsatisfactory for many patients, there is a need for new therapeutic approaches for the management of moderate or severe cancer pain.

Recent studies indicate that intramuscular (into a muscle) or subcutaneous (under the skin) injections of tetrodotoxin (TTX) may reduce pain in cancer patients who did not respond to standard therapies.

The current proposed study (TEC-006) is designed to 1) demonstrate in a double-blind, placebo-controlled trial that the subcutaneous 30 μg b.i.d. dose of TTX for 4 days is effective in reducing pain outcome and improving quality of life; 2) characterize the onset and duration of analgesia, and 3) demonstrate that TTX is well tolerated in patients with inadequately controlled cancer-related pain.

Condition or disease Intervention/treatment Phase
Pain Cancer Biological: Tetrodotoxin Biological: Placebo Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 165 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre , Randomized, Double-blind, Placebo-controlled, Parallel-design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (TTX) for Moderate to Severe Inadequately Controlled Cancer-related Pain
Study Start Date : April 2008
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Arm Intervention/treatment
Active Comparator: Tetrodotoxin Biological: Tetrodotoxin
30 µg twice daily for 4 days
Other Name: TTX

Placebo Comparator: Sugar injection Biological: Placebo
2 mL subcutaneous injection twice daily for 4 days

Primary Outcome Measures :
  1. Efficacy: Composite-endpoint will be an evaluation that combines pain outcome and quality of life. Pain intensity will be used a co-primary endpoint. Safety as assessed by the analysis of AEs, 12-lead ECG, and abnormal lab values. [ Time Frame: Dec2010 ]

Secondary Outcome Measures :
  1. The period of onset of pain response as reported by responders. [ Time Frame: Dec2010 ]
  2. The number of days a subject meets the definition of pain response. [ Time Frame: Dec2010 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  1. Male or female 18 years of age and over.
  2. Inpatient or outpatient with a diagnosis of cancer.
  3. Stable but inadequately controlled pain with current therapy for at least two weeks.
  4. Experiencing somatic, visceral and/or neuropathic pain related to cancer.
  5. Baseline pain intensity, as assessed by Question #3 of the Brief Pain Inventory (BPI) that meets the definition of "moderate" (score of 4-5) or "severe" (score of 6-10) pain.
  6. Life expectancy of at least 3 months.
  7. Ability to communicate well with the investigator and to comply with the requirements (restrictions, appointments, and examination schedule) of the entire study.
  8. Signed informed consent document (prior to any study-related procedures being performed).

Exclusion criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

  1. Planned initiation of chemotherapy, radiotherapy, or bisphosphonates within 30 days prior to randomization.
  2. Use of anaesthetics.
  3. Use of lidocaine and other types of antiarrhythmic drugs.
  4. Use of scopolamine and acetylcholinesterase-inhibiting drugs such as physostigmine.
  5. History of CO2 retention, or SaO2 <80% either on room air or O2 of not greater than 2-4 L/min by nasal cannula.
  6. Second- or third-degree heart block or prolonged QTc interval (corrected for rate) on screening ECG (confirmed > 450 msec on repeated occasion) or any other active cardiac arrhythmia or abnormality that could constitute a clinical risk.
  7. Coagulation or bleeding defects if, in the opinion of the investigator, this represents a risk to the subject considering the subcutaneous (s.c.) route of administration.
  8. Known hypersensitivity to puffer fish, tetrodotoxin and/or its derivatives.
  9. Use of an investigational agent within 30 days prior to screening or is scheduled to receive an investigational drug other than tetrodotoxin during the course of the study.
  10. Females who are lactating or at risk of pregnancy (i.e., sexually active with fertile males and not using an adequate form of birth control).
  11. Females with a positive serum pregnancy test at screening or positive urine pregnancy test on admission to study site.
  12. Any other condition that, in the opinion of the investigators, is likely to interfere with the successful collection of the measures required for the study or poses a risk to the patient.
  13. Men with glomerular filtration rate (GRF) less than 60 mL/min/1.73 m2 and women with GFR less than 50 mL/min/1.73 m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00725114

Layout table for location information
Canada, British Columbia
WEX Pharmaceuticals Inc.
Vancouver, British Columbia, Canada, V6C 1G8
Sponsors and Collaborators
Wex Pharmaceuticals Inc.
Layout table for investigator information
Study Chair: Dr. Neil Hagen, MD, FRCPC Tom Baker Cancer Centre
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wex Pharmaceuticals Inc. Identifier: NCT00725114    
Other Study ID Numbers: TEC-006
First Posted: July 30, 2008    Key Record Dates
Last Update Posted: July 9, 2014
Last Verified: August 2012
Keywords provided by Wex Pharmaceuticals Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Cancer Pain
Neurologic Manifestations
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action